Detalles de la búsqueda
1.
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
Lancet
; 402(10416): 1979-1990, 2023 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898137
2.
Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
Am Heart J
; 263: 73-84, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192697
3.
Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
Catheter Cardiovasc Interv
; 101(4): 687-700, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36807456
4.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Lancet
; 394(10205): 1243-1253, 2019 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31488372
5.
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Lancet
; 392(10149): 737-746, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30170848
6.
Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
Lancet
; 392(10150): 849-856, 2018 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30170854
7.
Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials.
BMC Cardiovasc Disord
; 19(1): 226, 2019 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31619181
8.
Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
Lancet
; 387(10013): 31-9, 2016 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26470647
9.
Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
Catheter Cardiovasc Interv
; 89(6): 994-1002, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27527508
10.
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
Circulation
; 131(1): 74-81, 2015 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25411159
11.
Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
Lancet
; 393(10184): 1934-1935, 2019 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31084963
12.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Lancet
; 384(9960): 2111-22, 2014 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189359
13.
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
Cardiovasc Revasc Med
; 34: 3-10, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33653633
14.
Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.
Clin Res Cardiol
; 111(7): 806-815, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35220449
15.
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Int J Cardiol
; 334: 37-41, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887341
16.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
JACC Cardiovasc Interv
; 14(6): 639-648, 2021 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33727005
17.
Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials.
Eur Heart J Qual Care Clin Outcomes
; 6(1): 81-88, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228186
18.
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
J Am Heart Assoc
; 8(22): e013607, 2019 11 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31696762
19.
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
EuroIntervention
; 14(6): 692-699, 2018 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205157
20.
Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.
Clin Cardiol
; 41(5): 569-575, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29527709